AMR.Solutions
Menu-01-01

R&D Insight

BARDA seeks to support a VC-like mechanism for Medical Countermeasure (MCM) innovation / Your chance to provide input!

Dear All, BARDA is (yet again!) pushing the envelope with novel ways to support innovation. Their DRIVe group has just released an RFI in which they request input on their plans to create a VC-like mechanism through a third party to support innovation in the MCM (medical countermeasure) space. Go here for the complete RFI, but I’ll reproduce a

Read More »
30 October 2019 No Comments

Treating CNS infections: An NIH/DoD workshop on strategies for crossing the blood-brain barrier

Dear All: Sponsored by NIH (NIAID, NINDS, NHLBI, NCATS) and DoD (DTRA), a 2-day workshop on CNS infections and ways to penetrate the blood-brain barrier has just been announced for 21-22 Aug 2018. Full details are found online at http://www.cvent.com/d/wgq9j7. The preliminary agenda online looks fascinating and shows planned discussions of viral encephalitis (e.g., West Nile),

Read More »
9 May 2018 No Comments

Calls for proposals: US CDC, UK-China, Wellcome Trust

Dear All: As we head into the Easter and Passover weekend, three new calls for proposals have emerged! Perhaps one of these is for you? The US CDC has released a Broad Agency Announcement (FY2018-OADS-BAA) seeking proposals for projects across a range of areas (diagnostics, transmission, microbiome disruption, resistance genes in the environment, and stewardship). Initial proposals

Read More »
30 March 2018 No Comments

UK-China AMR Collaboration Competition

Dear All:  It is great to see that the UK Department of Health (DH) and the Chinese Ministry of Science and Technology (MoST) have today announced the size, scope and eligibility for the UK-China AMR Collaboration that was initially announced in 2016. DH will to invest up to £10 million in UK businesses and MoSt will provide to 60 million

Read More »
16 August 2017 No Comments

Using Real-World Evidence: FDA Workshop on 13 Sep 2017

Dear All:  There is a newly announced FDA workshop on 13 Sep on using real-world evidence. Here is the link and I’ve also reproduced the key background text below my signature. This is of interest to the antibacterial community as our reliance on non-inferiority trials for the majority of our data means that we are often going to want

Read More »
29 July 2017 No Comments

CARB-X funding round #1, SDRI 2017, & Antibiotic-tainted seafood

Dear All: Just in case you missed the 30 March annoucement, see at right a snapshot of the first 11 Powered by CARB-X funded companies. Initial funding is $24m, with  potentially a further $24m if the companies hit their milestones. With the funds provided by the companies themselves, the total potential investment is $75m. This is just the start:

Read More »
2 April 2017 No Comments
Scroll to Top